Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
---|
02/10/2015 | US8951986 Salts of HIV inhibitor compounds |
02/10/2015 | US8951985 Compounds and pharmaceutical compositions for the treatment of viral infections |
02/10/2015 | US8951984 Oligonucleotides for modulation of target RNA activity |
02/10/2015 | US8951979 Pain treatment using ERK2 inhibitors |
02/10/2015 | US8951978 Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity |
02/10/2015 | US8951977 Amorphous roxithromycin composition |
02/10/2015 | US8951976 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
02/10/2015 | US8951972 FGFR1 extracellular domain combination therapies for lung cancer |
02/10/2015 | US8951969 Compositions and methods for treating centrally mediated nausea and vomiting |
02/10/2015 | US8951965 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
02/10/2015 | US8951747 Method for modulating activity of T lymphocytes |
02/10/2015 | US8951636 Composite particles which contain both cellulose and inorganic compound |
02/10/2015 | US8951583 Compositions for topical treatment |
02/10/2015 | US8951582 Compositions for topical treatment |
02/10/2015 | US8951577 Antimicrobial hydrochloric acid catheter lock solution and method of use |
02/10/2015 | US8951567 Sol-gel phase-reversible hydrogel templates and uses thereof |
02/10/2015 | US8951564 Galenic form suitable for absorbing, in a specific manner, the undesirable molecules in the digestive tract |
02/10/2015 | US8951561 Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) |
02/10/2015 | US8951560 Isoflavone nanoparticles and use thereof |
02/10/2015 | US8951557 Sustained release solid formulations and methods of manufacturing the same |
02/10/2015 | US8951556 Oral drug delivery system |
02/10/2015 | US8951555 Controlled release hydrocodone formulations |
02/10/2015 | US8951553 Composition for promoting vascular smooth muscle relaxation |
02/10/2015 | US8951552 In situ film-forming bioactive solutions of absorbable multiblock copolymers |
02/10/2015 | US8951551 Multiribbon nanocellulose as a matrix for wound healing |
02/10/2015 | US8951550 Dietary formulations and methods for treatment of inflammation and other disorders |
02/10/2015 | US8951545 Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery |
02/10/2015 | US8951536 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
02/10/2015 | US8951532 A25 bacteriophage lysin |
02/10/2015 | US8951529 Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases |
02/10/2015 | US8951528 Immune response modifier conjugates |
02/10/2015 | US8951514 Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
02/10/2015 | US8951507 Formulation with irritation reducing action comprising bisabolol and [6]-paradol |
02/10/2015 | US8951504 (trimethoxyphenylamino) pyrimidinyl formulations |
02/10/2015 | US8951499 Trifunctional reagent for conjugation to a biomolecule |
02/10/2015 | US8950583 Method to remove heavy metals from a mammal |
02/10/2015 | CA2817249C Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof |
02/10/2015 | CA2700905C C7-substituted camptothecin analogs |
02/10/2015 | CA2673137C Prodrug salts of 2,4-pyrimidinediamine compounds and their uses |
02/10/2015 | CA2672956C Calcium receptor modulating agents |
02/10/2015 | CA2672134C Solid medicinal preparation containing mannitol or lactose |
02/10/2015 | CA2671670C Sustained-release composition and method for producing the same |
02/10/2015 | CA2669846C Materials and methods for introducing genetic material into living cells |
02/10/2015 | CA2668414C Methods of treating dermatological disorders or conditions |
02/10/2015 | CA2668280C 5-hydroxymethyl-oxazolidin-2-one derivatives |
02/10/2015 | CA2666375C 3-aminoimidazo[1,2-a]pyridine derivatives having an sglt1- and sglt2- inhibiting action for the treatment of type 1 and type 2 diabetes |
02/10/2015 | CA2660762C Transdermal application of triazines for controlling infections with coccidia |
02/10/2015 | CA2658400C Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies |
02/10/2015 | CA2653662C Spirocyclic nitriles as protease inhibitors |
02/10/2015 | CA2648895C Camptothecin-analog with a novel, "flipped" lactone-stable, e-ring and methods for making and using same |
02/10/2015 | CA2632437C 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumours |
02/10/2015 | CA2630823C Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
02/10/2015 | CA2619040C Crystalline and amorphous sodium atorvastatin |
02/10/2015 | CA2607802C Pharmaceutical formulation of apomorphine for buccal administration |
02/10/2015 | CA2600350C Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
02/10/2015 | CA2586553C Nasal sprayer containing a formulation with olopatadine |
02/10/2015 | CA2547963C Methods of treating an inflammatory-related disease |
02/10/2015 | CA2545572C Compositions of oligosaccharides for reducing pathogenic bacteria in the gastrointestinal tract of companion animals |
02/10/2015 | CA2537473C Cytokine involved in epithelial-mesenchymal transition |
02/10/2015 | CA2523363C Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
02/10/2015 | CA2489860C Use of an antibody against s100a8 or s100a9 as chemotactic factor inhibitor for modulating inflammatory reactions |
02/08/2015 | CA2857725A1 Heat sterilization techniques for chlorhexidine based antiseptic formulations |
02/05/2015 | WO2015017821A2 Therapeutically active compounds and their methods of use |
02/05/2015 | WO2015017812A1 Methods for the treatment of solid tumors |
02/05/2015 | WO2015017803A1 Compositions and methods for treating disease states associated with activated t cells and/or b cells |
02/05/2015 | WO2015017762A1 Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
02/05/2015 | WO2015017715A1 Drug delivery method |
02/05/2015 | WO2015017713A1 D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
02/05/2015 | WO2015017690A1 Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
02/05/2015 | WO2015017661A1 Compound and methods for treating long qt syndrome |
02/05/2015 | WO2015017607A2 METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
02/05/2015 | WO2015017589A1 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions |
02/05/2015 | WO2015017575A2 Compositions and methods for inducing urinary voiding and defecation |
02/05/2015 | WO2015017565A1 Treatment of multiple sclerosis with combination of laquinimod and flupirtine |
02/05/2015 | WO2015017549A1 Treating an atypical protein kinase c enzyme abnormality |
02/05/2015 | WO2015017546A1 Selective histone deactylase 6 inhibitors |
02/05/2015 | WO2015017502A1 Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
02/05/2015 | WO2015017466A1 Formulation of syk inhibitors |
02/05/2015 | WO2015017460A1 Polymorph of syk inhibitors |
02/05/2015 | WO2015017441A1 Pharmaceutical compositions of ranolazine and dronedarone |
02/05/2015 | WO2015017423A2 Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
02/05/2015 | WO2015017412A1 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
02/05/2015 | WO2015017407A1 Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase |
02/05/2015 | WO2015017393A2 Piperazine derivatives as hiv protease inhibitors |
02/05/2015 | WO2015017382A1 Hepatitis c virus inhibitors |
02/05/2015 | WO2015017378A2 Novel copper-cysteamine and methods of use |
02/05/2015 | WO2015017351A1 Method of treating hypertrophic cardiomyopathy |
02/05/2015 | WO2015017340A2 Low swell tissue adhesive and sealant formulations |
02/05/2015 | WO2015017336A1 Combination and method for administration to an animal |
02/05/2015 | WO2015017335A1 Azaindole compounds as modulators of rorc |
02/05/2015 | WO2015017328A2 Organophosphates for treating afflictions of the skin |
02/05/2015 | WO2015017311A1 Dot1l probes |
02/05/2015 | WO2015017302A2 Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors |
02/05/2015 | WO2015017073A1 Nutritional compositions for enhancing brain development |
02/05/2015 | WO2015016938A1 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid |
02/05/2015 | WO2015016818A1 Novel azolo-1,2,4-triazine derived antiviral oral therapeutic |
02/05/2015 | WO2015016789A1 Powder formulation of valganciclovir |
02/05/2015 | WO2015016750A1 Carbamoylphenyl derivatives for stopping, avoiding and preventing bleeding or for strengthening the hemostatic system |
02/05/2015 | WO2015016729A1 Urea compounds and their use as faah enzyme inhibitors |
02/05/2015 | WO2015016728A1 Urea compounds and their use as faah enzyme inhibitors |